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In Brief
Tong et al. demonstrate that the DNA damage response kinases ATM and ATR are required for the presence of telomerase at telomeres in human cells. Replication fork stalling triggers ATRmediated telomerase recruitment, and phosphorylation of the telomere-binding protein TRF1 at serine 367 also regulates the presence of telomerase at telomeres.
INTRODUCTION
Vertebrate telomeres are repetitive TTAGGG DNA sequences located at the ends of chromosomes, which protect the coding regions of DNA. In mammalian germline cells and 85% of cancers, telomere length is maintained by the dimeric ribonucleoprotein telomerase, which catalyzes the addition of TTAGGG repeats to counteract telomere shortening and cellular senescence (Shay and Bacchetti, 1997; Kim et al., 1994; Wenz et al., 2001) . The minimal catalytic core of human telomerase consists of the telomerase reverse transcriptase protein (hTERT), telomerase RNA (hTR), and the protein dyskerin (Cohen et al., 2007) .
The differentiation of telomeres from broken chromosome ends is conferred by a family of six telomere-specific binding proteins collectively termed ''shelterin'' (de Lange, 2005) . This complex consists of the double-stranded binding proteins TRF1 and TRF2, the single-stranded binding proteins POT1 and TPP1, the bridging protein TIN2 that links these two groups of proteins, and Rap1 (reviewed in Palm and de Lange, 2008) . TRF1 protects the telomere and negatively regulates telomerase-mediated telomere lengthening (van Steensel and de Lange, 1997; Smogorzewska et al., 2000; Ancelin et al., 2002; Karlseder et al., 2002) . TRF1 also facilitates the progression of the replication machinery; deletion of TRF1 increases replication fork stalling, leading to ATR kinase activation and a ''fragile telomere'' phenotype (Sfeir et al., 2009; Martínez et al., 2009) . The TRF1-mediated repression of the ATR response requires recruitment of the shelterin components TIN2 and the TPP1/POT1 heterodimer (Zimmermann et al., 2014) .
TPP1 and POT1 also have roles in mediating telomere-length regulation. A surface on the N-terminal oligonucleotide/oligosaccharide-binding (OB) domain of TPP1 termed the TEL patch activates telomerase by stimulating telomerase processivity and providing a direct binding site for telomerase recruitment to telomeres; mutation of the TEL patch can lead to telomere shortening syndromes characterized by bone marrow failure (Abreu et al., 2010; Nandakumar et al., 2012; Zhong et al., 2012; Kocak et al., 2014; Guo et al., 2014; Dalby et al., 2015) . Additionally, mutation analyses at sites independent of the TEL patch have implicated TPP1 as part of a telomere-length-dependent feedback loop that regulates telomere-length homeostasis (Sexton et al., 2014) . A mutant form of POT1 that abrogates binding to singlestranded DNA (POT1DOB) deregulated telomere-length control (Loayza and De Lange, 2003) , indicating that the DNA-binding capability of POT1 is vital as a negative regulator of telomere length. The impact of human POT1 on telomere length is complex, since both depletion and overexpression of POT1 lead to telomere lengthening (Ye et al., 2004; Veldman et al., 2004; Colgin et al., 2003; Armbruster et al., 2004) . POT1 function as a positive or negative regulator of telomerase activity at the telomere depends on its position of binding relative to the DNA 3 0 end
Cell (legend continued on next page) and is also modulated by its binding partner, TPP1 Wang et al., 2007; Lei et al., 2005; Kelleher et al., 2005) . Telomerase action at the telomere is highly regulated; it preferentially elongates the shortest telomeres, and recruitment of the enzyme complex to the telomere occurs in mid-S phase of the cell cycle (Bianchi and Shore, 2007; Britt-Compton et al., 2009; Teixeira et al., 2004; Hemann et al., 2001; Tomlinson et al., 2006; Já dy et al., 2006) . In both budding and fission yeasts, the preference of telomerase to extend the shortest telomeres requires the activity of Tel1, the yeast homolog of human ATM (Sabourin et al., 2007; Hector et al., 2007; Arneri c and Lingner, 2007) . ATM and ATR are kinases within the phosphatidylinositol-3 kinaserelated kinase (PIKK) family, which regulates cellular responses to DNA damage, mRNA decay, and nutrient-dependent signaling (Lovejoy and Cortez, 2009 ). Activation of these DNA damage pathways is dampened at telomeres; in mammalian cells, TRF2 represses activation of ATM while POT1 represses ATR (Karlseder et al., 2004; Celli and de Lange, 2005; Denchi and de Lange, 2007; Guo et al., 2007; Okamoto et al., 2013) . Nevertheless, there is a large amount of evidence that their yeast homologs play a positive role in facilitating telomere extension by telomerase (Moser et al., 2009 (Moser et al., , 2011 Yamazaki et al., 2012; Churikov et al., 2013) .
It is not known whether the role of the ATM and ATR pathways in recruiting telomerase is conserved in mammals. Although ATM deficiency or ATR mutations can induce telomere shortening or instability in human and mouse cells (Metcalfe et al., 1996; Smilenov et al., 1997; Wong et al., 2003; Wu et al., 2007; Pennarun et al., 2010) , these kinases were reported to be dispensable for elongation of the shortest telomeres in mouse models (Feldser et al., 2006; McNees et al., 2010) . Also, immortalized cell lines from human patients with ATM mutations are able to maintain their telomeres with telomerase, albeit at short lengths (Sprung et al., 1997) . Nonetheless, there is evidence that TRF1-mediated telomere-length regulation in human cells involves ATM. Inhibition of human ATM resulted in increased TRF1 at the telomere, and phosphorylation of TRF1 on serine 367, an ATM/ATR target site, reduced the interaction of TRF1 with telomeres and abrogated its ability to inhibit telomere lengthening (McKerlie et al., 2012; Wu et al., 2007) .
In this study, we report that both ATM and ATR are required for the recruitment of human telomerase to telomeres.
RESULTS

ATM and ATR Are Both Required for the Presence of Human Telomerase at Telomeres
We used fluorescence in situ hybridization (FISH) to detect human telomerase RNA (hTR) in combination with a probe for telomeres to visualize the presence of endogenous telomerase at telomeres in HEK293T cells (Stern et al., 2012) (Figure 1A ). Depletion of ATM and ATR using small interfering RNA (siRNA) resulted in reduction of levels of each protein by 95% and 80%, respectively ( Figure 1B) , without causing significant perturbations in progression of the cells through the cell cycle (Figure S1A) . Depletion of either kinase resulted in a significant decrease in telomerase recruitment to telomeres in asynchronously growing cells ( Figures 1A and 1C) . The roles of both ATM and ATR in telomerase recruitment were confirmed with a second siRNA against each protein ( Figure 1D ).
The involvement of the kinase activities of both ATM and ATR were demonstrated by using the kinase inhibitors KU-55933 and VE-822 ( Figures 1A and 1E ) at concentrations sufficient to inhibit ATM autophosphorylation and ATR activation, respectively (Figure S1B) , without inhibiting related kinases (1.5 mM for KU-55933 and 0.5 mM for VE-822; Hickson et al., 2004; Fokas et al., 2014) .
Telomerase recruitment across the cell cycle was examined by synchronizing cells at the G1/S boundary with overnight thymidine and aphidicolin treatments, followed by release from the cell-cycle block and harvest at hourly intervals ( Figure S1A ). Telomerase presence at the telomere peaks in mid-S phase (Figure 1F) , as previously described (Tomlinson et al., 2006; Já dy et al., 2006) . Depletion of ATM abolished recruitment of telomerase to the telomere across all phases of the cell cycle ( Figures  1F and S1C ). Since this synchronization procedure is likely to cause DNA damage, we confirmed these observations by sorting ATM-and ATR-depleted cells by flow-activated cell sorting (FACS) into different cell-cycle phases based on DNA content ( Figure S1A ). Despite reduced numbers of hTR-telomere foci in control cells across the cell cycle (discussed further below), lack of either kinase again resulted in a large decrease in telomerase recruitment, particularly in S phase ( Figures 1G and 1H ). Reduction of hTR-telomere colocalizations across the cell cycle after ATM depletion was also demonstrated in a second human cell line, HeLa ( Figures S1D-S1G ). These results provide direct evidence that telomere shortening in telomerase-positive human cells defective in ATM and ATR activity is at least partially the result of diminished recruitment of telomerase to telomeres.
ATM Effect on Telomerase Recruitment Is Partially Mediated by TRF1
It is known that TRF1 is a substrate of ATM and/or other PIKK kinases, and such phosphorylation events lead to changes in TRF1 localization and telomere length (Kishi et al., 2001; Wu et al., 2007; McKerlie et al., 2012) . To investigate whether these changes in telomere length are due to changes in the presence of telomerase at telomeres, we knocked down TRF1 by (E) Average telomerase co-localization with telomeres in S phase synchronized 293T cells after treatment with DMSO vehicle (gray), 1.5 mM KU-55933 (light yellow), or 500 nM VE-822 (dark yellow); *p < 0.05. Figure 1G . In all panels, data are presented as the mean of three independent experiments ± SD. See also Figure S1 . 2E , and S2F-S2H). TRF1 knockdown also resulted in increased hTR/telomere co-localizations in G1 phase in FACS-sorted cells, demonstrating that TRF1 is involved in the signaling pathway that restricts telomerase presence at the telomere to S phase. To confirm that ATM and TRF1 function in the same pathway, we performed a double knockdown of ATM and TRF1 ( Figures  S2D and S2E ). If ATM involvement in telomerase recruitment is mediated by the phosphorylation and removal from the telomere of TRF1 (Wu et al., 2007) , we predict that depletion of TRF1 will render telomerase insensitive to the absence of ATM. Simultaneous knockdown of ATM and TRF1 significantly elevated the levels of telomerase recruitment in S and G2/M phases compared to depletion of ATM alone (p = 0.0018 and p = 0.0097, respectively) (Figures 2F and 2G) . A full recovery of recruitment was not observed in S phase cells; this may be partially due to residual TRF1 remaining after knockdown, but it also indicates that other TRF1-independent ATM substrates may be involved in telomerase recruitment (discussed further below).
Phosphorylation of TRF1 at Serine 367 Controls TRF1 and Telomerase Localization to Telomeres
We have demonstrated that phosphorylation of serine 367 of TRF1 results in localization of TRF1 to proteasome centers for degradation, resulting in telomere elongation (McKerlie et al., 2012) . To demonstrate that such elongation events are due to changes in telomerase localization to telomeres, we transiently expressed in 293T cells similar levels of myc-tagged wild-type (WT) TRF1 or TRF1 containing mutations at S367 that either abolish (S367A) or mimic (S367D) phosphorylation at this residue ( Figures 3A, S3A , and S3B). Exogenous TRF1 was expressed at levels 10-to 15-fold greater than endogenous TRF1 ( Figure 3A) ; this level of overexpression was sufficient for replacement of endogenous TRF1 with myc-tagged exogenous TRF1 at 25% of telomeres ( Figures 3B-3E ). S367D TRF1 demonstrated lower telomere association across all phases of the cell cycle than WT or S367A TRF1 ( Figures 3B, 3D , and S3C), consistent with its inability to bind telomeric DNA in vitro (McKerlie et al., 2012) . Endogenous TRF1 was not depleted in this experiment, since we expected S367D TRF1 to behave in a dominant-negative manner to sequester endogenous TRF1 from the telomere, as has been observed for other DNA-binding-defective TRF1 mutants (van Steensel and de Lange, 1997); we confirmed this using immunofluorescence with an antibody against TRF1 (Figures 3C and 3E) . This observation coincided with an elevated level of telomerase recruitment in the presence of S367D TRF1 in G1 and G2/M phases ( Figures 3B, 3F , and S3C). Deregulation of telomerase recruitment in G1 and G2/M phases upon both TRF1 knockdown and S367D TRF1 expression was confirmed in a HeLa cell line stably expressing a small hairpin RNA (shRNA) against TRF1, together with shRNA-resistant S367D TRF1 (McKerlie et al., 2012 ; Figure S3D ).
Conversely, there was an 50% decrease in telomerase recruitment at S phase in the presence of phosphodeficient S367A TRF1 compared to WT TRF1 in both 293T and HeLa cells ( Figures 3F and S3D ). These data suggest that phosphorylation of TRF1 at serine 367 results in dissociation of a portion of TRF1 from telomeres during S phase and that this is necessary for full telomerase recruitment. This is supported by the slight increase in levels of endogenous TRF1 at telomeres in G2/M relative to S phase ( Figures 3C and 3E ). However, depletion of TRF1 levels at the telomere using siRNA, shRNA, or expression of the dominant-negative S367D TRF1 did not lead to substantially increased telomerase at the telomere during S phase ( Figures  2D-2G , S2H, 3E, 3F, and S3D), suggesting that removal of TRF1 is necessary, but not sufficient, for full telomerase recruitment in S phase. Together, our data show that the major function of TRF1 is in the displacement of telomerase from the telomere outside S phase, for which removal of the phosphate group at S367 appears to be necessary.
Stalled Replication Forks Trigger Telomerase Recruitment
The mechanism of telomerase regulation at the telomere by TRF1 may involve the known role of TRF1 in facilitating replication of telomeric DNA (Sfeir et al., 2009 ). Repetitive telomere repeats represent challenging templates for the canonical DNA replication machinery, often resulting in stalled replication forks and recruitment of the single-stranded DNA-binding protein RPA and activation of ATR (Ohki and Ishikawa, 2004; Sfeir et al., 2009; Fouché et al., 2006; Ivessa et al., 2002) ; in mammalian cells, this phenotype is exacerbated by depletion of TRF1 (Sfeir et al., 2009; Martínez et al., 2009) . Our observation that treatment of cells with aphidicolin and thymidine results in an apparent increase in numbers of hTR-telomere foci (Figures 1F and 1G) suggests that DNA damage directly regulates telomerase recruitment. To directly examine whether this effect can be attributed to stalled replication forks, we subjected (E) Telomerase co-localization with telomeres in 293T cells, treated with control (gray) or TRF1 (blue) siRNA; cells were stained with the DNA dye VyBrant DyeCycle Violet and isolated into the cell-cycle phases with FACS. The control data are the same as those in Figure 1G , since these experiments were performed simultaneously. (F) FISH for hTR (green) and telomeres (red) in 293T cells treated with control or combined ATM and TRF1 siRNAs. Cells were either asynchronous or synchronized with thymidine and aphidicolin and harvested 3-4 hr (S phase) or 7 hr (G2/M) after release from the G1/S boundary. Co-localizations are indicated by the white arrows in the merge row. Scale bar, 10 mm. (G) Quantitation of (F); average telomerase-telomere co-localizations after control (gray), ATM only (red), TRF1 only (blue), and ATM/TRF1 (green) siRNAs, in asynchronous, S phase, or G2/M phase cell populations; n = 4; **p < 0.01. Data are presented as the mean of three independent experiments except where indicated otherwise, ± SD. See also Figure S2 .
asynchronous 293T cells to a much shorter period of aphidicolin treatment. Telomerase recruitment increased 2-fold after 30-min treatment with 0.5 mg/ml aphidicolin compared to controls, despite no significant change in cell-cycle profile, and this increase was dependent upon ATR ( Figures 4A, 4B , and S4). Phosphorylation of the ATR target protein Chk1 demonstrated that a 30-min treatment with aphidicolin was sufficient to cause replication problems and activate the ATR pathway ( Figure 4C ). To ensure that this aphidicolin treatment did not result in damage signaling from DNA double-strand breaks (DSBs) arising from collapsed replication forks, we examined activation of the ATM-Chk2 DSB response pathway ( Figure 4C ). In all panels, data are presented as the mean of three independent experiments ± SD. See also Figure S3 .
Aphidicolin treatment caused a moderate activation of ATM and Chk2 phosphorylation ( Figure 4C , lane 2, and Figure 4D ), but this was abolished by knockdown of ATR ( Figure 4C , lane 5, and Figure 4D ), indicating that it results from the direct activation of ATM by ATR that is known to occur upon replication fork stalling (Stiff et al., 2006) rather than from DSB formation. In addition, induction of DSBs by gamma irradiation triggered Figure 4A , probed for ATR, pS1981 ATM, ATM, pT68 Chk2, Chk2, pS345 Chk1, Chk1, and vinculin as a control.
(D) Quantitation of ATM activation (pS1981 ATM levels) from blot in Figure 4C ; *p = 0.028. In all panels, data are presented as the mean of three independent experiments ± SD. See also Figure S4 .
robust ATR-independent ATM activation ( Figure 4C , lanes 3 and 6) that did not result in increased telomerase recruitment to telomeres ( Figures 4A and 4B) . Together, our data demonstrate that an increase in stalled replication forks and the resulting ATR signaling result in an increase in telomerase presence at the telomere. This is consistent with the telomere lengthening previously observed in telomerase-positive human cells after long-term treatment with aphidicolin (Sfeir et al., 2009 ).
Telomere Elongation Triggered by POT1 Mutation Is Dependent on ATM As a TRF1-independent mechanism of exposing single-stranded DNA at telomeres, we infected HeLa204 cells (Takai et al., 2010 ) with a retrovirus encoding the human POT1 construct myc-POTDOB (Loayza and De Lange, 2003) . Myc-POT1DOB contains a truncation of one of the two POT1 OB folds, allowing POT1 to localize to telomeres but abolishing its ability to bind single-stranded telomeric DNA and abrogating POT1-mediated telomere-length regulation (Loayza and De Lange, 2003; Zhong et al., 2012) . As expected, myc-POTDOB caused dramatic telomere-length elongation over 35-37 population doublings (PDs) ( Figure 5A ). Simultaneous expression of three independent shRNAs against ATM (Figure 5B ) completely abrogated telomere lengthening ( Figure 5A ), demonstrating that telomerase-mediated telomere lengthening in this context is dependent on ATM.
ATM and ATR Also Affect Telomerase Complex Assembly
The inability of TRF1 depletion to completely rescue telomerase recruitment after ATM silencing ( Figure 2G ) implies that ATM can affect other TRF1-independent pathways of telomerase regulation. We therefore investigated the levels of cellular telomerase components and their assembly capabilities. Measurement of total cellular hTR levels with a dot blot using an hTR-specific probe revealed a slight inhibitory effect of TRF1 siRNA on hTR abundance ( Figures 6A, 6B , S5A, and S5B). The amount of hTR recovered after immunoprecipitation with an antibody against hTERT ( Figures 6A and 6C ) reflected the levels of hTR in crude lysates, indicating that TRF1 depletion did not impact assembly of hTERT and hTR into an active complex. Conversely, treatment with ATM siRNA did not affect cellular hTR abundance ( Figures 6A and 6B ), but it reduced telomerase complex assembly by 50% across all phases of the cell cycle ( Figures 6A and  6C ). Double ATM/TRF1 knockdown also resulted in a similar assembly defect ( Figures 6D, S5C , and S5D), indicating that TRF1 is unlikely to be the ATM target responsible for this effect. Telomerase activity, measured by a direct non-PCR assay (Cohen and Reddel, 2008) and normalized against the amount of hTR recovered in hTERT immunoprecipitates, revealed no significant changes in the specific activity of telomerase after depletion of either ATM or TRF1 ( Figures 6E, 6F , S5E, and S5G).
We also examined the effect of ATR silencing on levels of cellular telomerase RNA and telomerase assembly. Treatment with two different ATR siRNAs ( Figure S5H ) reduced telomerase complex assembly by up to 50% in unsynchronized and G1 phase cells ( Figures 6G and 6H ) without affecting total hTR levels or specific activity of telomerase ( Figures 6I and S5I-S5K ).
DISCUSSION
In this study, we have demonstrated that ATM and ATR are both necessary for full telomerase recruitment to telomeres in human cell lines. This conclusion is supported by an independent study using complementary approaches in which ATM was demonstrated to be necessary for telomerase-mediated telomere addition in both human and mouse cells (Lee et al., 2015) . This provides an explanation, at least in part, for the long-standing observation of short telomeres in the ATM-deficient cells of ataxia telangiectasia (AT) patients (Metcalfe et al., 1996; Smilenov et al., 1997) and the telomere shortening observed upon inhibition of ATM in telomerase-positive immortal human cell lines (Wu et al., 2007) . Consistently, while AT patient cells can become immortalized by activation of telomerase, most of these cell lines harbor very short telomeres (Sprung et al., 1997) .
Our data show that TRF1 is involved in the signaling pathway restricting telomerase access to the telomere to S phase; loss of TRF1 results in an increase in telomerase at the telomere in both G1 and G2/M phases. Evidence from this and previous studies suggests that phosphorylation of TRF1 at serine 367 results in partial TRF1 dissociation from telomeres and its degradation; removal of this phosphate is necessary for correct cell-cycle control of telomerase presence at the telomere. Constitutive expression of a phosphomimetic of S367 TRF1 also leads to inappropriate retention of telomerase at the telomere outside S phase, leading to a telomere-length increase (Wu et al., 2007; McKerlie et al., 2012 ; this study; Figure 3 ). The mechanism for this regulatory function of TRF1 may include its known role in facilitating telomere replication; TRF1 dissociation from telomeres induces replication fork stalling that activates ATR (Sfeir et al., 2009 ), and we provide evidence that replication fork stalling leads to an ATR-dependent increase in telomerase recruitment (Figure 4) . The control of telomere replication and telomerase presence at the telomere by human TRF1 ( Figure 7A ) appears analogous to the situation in Schizosaccharomyces pombe, in which deletion of the double-stranded telomeric-binding protein Taz1 results in stalled telomeric replication forks (Miller et al., 2006) and leads to deregulation of the cell-cycle control of telomerase at the telomere (Dehé et al., 2012; Chang et al., 2013) . It is possible that in the absence of TRF1, aberrant products of stalled replication forks may persist into the subsequent G2/M and G1 phases, forming substrates for telomerase, as has been postulated in the case of Taz1 in S. pombe (Dehé et al., 2012) . It has been proposed that it is the tendency of the replication machinery to stall in repetitive DNA that forms the signal for telomerase recruitment specifically in S phase (Rog and Cooper, 2008; Verdun and Karlseder, 2006; Wu et al., 2007; Stern and Bryan, 2008; Dehé et al., 2012; Chang et al., 2013) . In this report, we provide direct evidence for this concept.
The downstream targets of ATR involved in mediating human telomerase recruitment have not yet been identified. Under stalled fork conditions, activated ATR is able to phosphorylate and activate ATM (Stiff et al., 2006, and Figures 4C and 4D) ; whether this phosphorylation of ATM participates in a positive feedback loop in removing TRF1 to accelerate ATR-mediated telomere length regulation remains to be investigated.
We also provide evidence that exposing telomeric singlestranded DNA in a different way, by overexpression of POT1 lacking its DNA-binding domain (Loayza and De Lange, 2003) , provides a signal for rapid telomere lengthening that is also ATM dependent ( Figure 5 ). Overexpression of POTDOB does not perturb binding of TRF1 to the telomere (Loayza and De Lange, 2003) ; the ATM-dependence of telomere lengthening in this context reinforces the notion that in addition to mediating telomerase recruitment through a TRF1-dependent pathway, there must be other TRF1-independent mechanisms by which ATM mediates telomerase localization at telomeres. This is consistent with the observation that lack of TRF1 does not completely rescue the telomerase recruitment defect caused by ATM depletion ( Figure 2G ).
We demonstrated that one TRF1-independent function of ATM is its impact upon the ability of hTR and hTERT to assemble into a functional enzyme complex (Figure 6 ), which is a prerequisite for localization of hTR to telomeres (Tomlinson et al., 2008) . ATR also plays a role in assembly of human telomerase; we do not know if the substrates of these two kinases in this process are the same. This role is reflected in a substantial decrease in the amount of hTR recovered after hTERT immunoprecipitation and in the total immunoprecipitated telomerase activity following ATM and ATR knockdown. The specific activity of telomerase remains unchanged, demonstrating that both ATM and ATR have no effect on telomerase catalytic activity, consistent with results in yeast (Chan et al., 2001) . No consensus PIKK phosphorylation motifs exist in the RNA-binding domain of hTERT, implying either that ATM or ATR can mediate telomerase assembly by targeting regions not in the RNA-binding domain or that they can regulate telomerase assembly by phosphorylating unknown substrates ( Figure 7B) .
Our data support a model incorporating multiple roles for ATM and ATR in the presence of human telomerase at telomeres (Figure 7) . One pathway involving both ATM and ATR is mediated by phosphorylation of TRF1 and its removal from the telomere, leading to replication fork stalling in telomeric DNA, which acts as a trigger for telomerase recruitment. A second pathway involves the role of ATM and ATR in facilitating telomerase assembly; additional phosphorylation targets of ATM, ATR, and other PIKKs in the telomerase recruitment process may remain to be identified. These data reveal that although it is important for telomeres to repress DNA damage signaling in order to avoid deleterious fusions, telomeres have also evolved the ability to carefully exploit aspects of DNA damage signaling pathways to regulate telomerase presence at the telomere. Increased understanding of regulation of telomerase assembly and access to the telomere may provide valuable insight in the process of developing highly specific cancer therapeutics.
EXPERIMENTAL PROCEDURES Plasmids
A TRF1 expression plasmid containing myc-tagged TRF1 was constructed by subcloning the TRF1 open reading frame from pCMV-GFP.hTRF1 plasmid into a pcDNA3.1/myc-HisB plasmid by In-Fusion cloning (Clontech Laboratories) according to the manufacturer's protocol. The mutation of serine 367 of TRF1 into alanine or aspartic acid was achieved using the Stratagene QuikChange II XL Site-Directed Mutagenesis kit. POT1 lacking the OB fold domain (POT1DOB) was expressed from the pLPC retroviral vector as described (Loayza and De Lange, 2003) , followed by infection with retrovirus vectors encoding shRNAs against ATM.
Cell Culture and Transfections HEK293T cells (from Dr. T. Adams, CSIRO), HeLa cells (American Type Culture Collection), HeLa204 cells (Takai et al., 2010) , or HeLa cells stably overexpressing TRF1 (McKerlie et al., 2012) were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) in a humidified 37 C incubator with 5% CO 2 . Cells were transfected with 90 pmol siRNA and 5.5 ml Lipofectamine RNAiMAX (Life Technologies) in 310 ml Opti-MEM (Life Technologies). siRNA sequences and catalog numbers are provided in Table S1 . Cells overexpressing myc-TRF1 were transfected with 2.5 mg WT TRF1 or 1.0 mg S367A/D TRF1 expression plasmid to ensure even protein expression levels, in DMEM for 34 hr. HEK293T cells were then synchronized at G1/S phase by adding 2 mM thymidine (Sigma-Aldrich) for 15 hr, releasing for 9 hr, and adding 0.5 mg/ml aphidicolin (Sigma-Aldrich) for 16 hr. Cells were harvested 3 hr after release and confirmed to be in mid-S phase by analysis of DNA content by flow cytometry on a FACSDiva (Becton Dickinson). HeLa cells grown in DMEM media (+ 10% FBS) were synchronized with medium containing 2 mM thymidine (Sigma-Aldrich) for 18 hr, released into thymidine-free DMEM (+ 10% FBS) for 9 hr and blocked with a second round of 2 mM thymidine for 15 hr. For kinase inhibitor treatment, 1.5 mM KU-55933 (Merck Millipore), 500 mM VE-822 (Selleckchem), or DMSO was added to cells released from synchronization for 3 hr before harvesting in mid-S phase. For cell sorting, cells were harvested and resuspended in Hank's balanced salt solution (Life Technologies) at a concentration of 1 3 10 6 cells/ml. The cells were stained with VyBrant DyeCycle Violet (Life Technologies) at a concentration of 1 ml per 1 3 10 6 cells at 37 C for 30 min before cell sorting using a BD FACSAriaIII Cell Sorter (BD Biosciences). Confirmation of cell-cycle phases was performed using the FACSDiva (Becton Dickinson).
Gamma Irradiation
Gamma irradiation was performed using the Gammacell 1000 Elite irradiator (Best Theratronics) with a 2012), with the exception that cells were fixed in 2% paraformaldehyde. Antibodies used for immunofluorescence were Myc-tag antibody (Cell Signaling, cat. no 2276; diluted 1:1,000) and polyclonal rabbit anti-TRF1 antibody (#370, de Lange lab; diluted 1:2,000). Staining was visualized on a Zeiss Axio Imager M1 microscope, with a Plan-Apochromat 633 oil objective (numerical aperture, 1.4), and an AxioCam MR digital camera (Carl Zeiss). Exposure times between treatments were consistent. For presentation purposes, pixel intensity histograms were adjusted in ZEN (Carl Zeiss), equally across all figure panels, and images were cropped in Adobe Photoshop. Colocalizing hTR and telomere foci were manually counted in >100 cells per treatment, and data were analyzed by Student's t test for pairwise comparison.
Automated Quantification of 3D Co-localizations between TRF1 and Telomeres
Immunofluorescence with anti-TRF1 antibody ( Figure 3C ) had sufficiently low background that quantitation of colocalizing foci was able to be automated using Metafer4 software (Metasystems) on a Zeiss Axioplan 2 microscope (Germany), with a 633 NA (1.4 Plan-Apochromat) oil objective, and appropriate filter cubes. DAPI stained nuclei were identified and background subtraction, image sharpening and TopHat transformation applied to the TRF1 immunofluorescence and telomere FISH channels. TRF1 immunofluorescence and telomere FISH foci were defined as foci of >0.1 mm 2 , >25% intensity over background, separated by a minimum distance of 0.5 mm. Co-localizations were events where the center of a TRF1 and a telomere FISH focus were %0.3 mm apart in three dimensions. Colocalizing TRF1 and telomere foci were counted in 200-300 cells per treatment, and data were analyzed by Student's t test for pairwise comparison.
Cell Lysis and Western Blot
The procedure for cell lysis and western blot was performed as previously described (Guo et al., 2014) , with the exception that the large proteins ATR and ATM were electrophoresed on 3%-8% gradient Tris-Acetate gels (Life Technologies) at 150 V for 90 min. The following antibodies were used: ATM (Abcam rabbit polyclonal, diluted 1:2,000, cat. no AB32420), ATR (Cell Signaling rabbit polyclonal, diluted 1:1,000, cat. no 2790), anti-pS1981 ATM (Abcam rabbit polyclonal, diluted 1:1,000, cat. no AB81292), pT68 Chk2 (Cell Signaling rabbit polyclonal, diluted 1:1,000, cat. no 2661), Chk2 (Merck-Millipore mouse monoclonal, diluted 1:1,000, cat. no 05-649), pS345 Chk1 (Cell Signaling rabbit polyclonal, diluted 1:1,000, cat. no 23485), Chk1 (Cell Signaling mouse monoclonal, diluted 1:1,000, cat. no 23605), TRF1 (rabbit polyclonal, #370, de Lange lab, diluted 1:2,000), vinculin (Sigma-Aldrich mouse monoclonal, diluted 1:10,000, cat. no V9131), and actin (Sigma-Aldrich rabbit polyclonal, diluted 1:10,000, cat. no A2103).
qRT-PCR RNA extraction was performed using the RNeasy Mini Kit (QIAGEN) according to manufacturer's protocol and RNA quantitated with a Nanodrop spectrophotometer (ThermoFisher ND-1000). RNA (1 mg) was digested with 1 U of DNase (I) Telomerase specific activity, derived from total telomerase activity ( Figure S5K ) normalized to levels of hTR after hTERT immunoprecipitation ( Figure 6H) . In all panels, data are presented as the mean of three independent experiments ± SD. See also Figure S5. A B Figure 7 . Model for ATM and ATR Involvement in Human Telomerase Recruitment to Telomeres (A) During S phase, ATM and/or other PIKKs phosphorylates TRF1 at S367, which leads to partial dissociation of TRF1 from telomeres (McKerlie et al., 2012; Wu et al., 2007) . Depletion of TRF1, together with its protein partners Tin2, TPP1, and Pot1, causes telomeric replication forks to stall, leading to recruitment of RPA and ATR (Sfeir et al., 2009; Martínez et al., 2009; Zimmermann et al., 2014) . ATR phosphorylates an unknown substrate to mediate telomerase recruitment. Replication fork stalling caused by aphidicolin treatment also leads to telomerase recruitment (this study) and telomere elongation (Sfeir et al., 2009 Analysis was carried out using the DDCt method with the Roche LightCycler 96 system software.
hTR Dot Blot Harvested cells were lysed with telomerase buffer (20 mM HEPES-KOH [pH 7.9], 300 mM KCl, 2 mM MgCl 2 , 10% v/v glycerol, 0.1% v/v Triton X-100, 5 mM DTT, 1 mM PMSF) at a concentration of 10 5 cells/ml, rotating at 4 C for 1 hr before centrifugation at 16,200 3 g at 4 C for 20 min. 10 ml of the lysate was applied to a GE Healthcare Life Sciences Amersham Hybond-XL membrane and probed with a 32 P-labeled oligonucleotide complementary to hTR as described previously (Jurczyluk et al., 2011) .
Telomerase Purification and Activity Assay
Immunopurification of telomerase was performed as described elsewhere (Cohen and Reddel, 2008) , using a polyclonal anti-hTERT antibody and elution with a competing peptide (both available from Abbexa). Activity of the eluted telomerase was measured in a 20 ml solution phase extension reaction containing 20 mM HEPES-KOH (pH 7.9), 2 mM MgCl 2 , 5 mM DTT, 1 mM spermidine, 0.1% Triton X-100, 0.5 mM dTTP, 0.5 mM dATP, 5 mM a-32 P-dGTP (198 Ci/mmol), and 1 mM DNA primer Bio-L-18GGG (5 0 -biotin-CTAGACC TGTCATCA(TTAGGG) 3 -3 0 ) for 60 min at 37 C. The reaction was terminated with EDTA and products isolated on Dynabead M280 streptavidin beads (Life Technologies), together with a 12-nt biotinylated control DNA, as described previously (Tomlinson et al., 2015) . Products were separated on a 10% acrylamide/7 M urea sequencing gel as described previously (Tomlinson et al., 2015) .
Telomere Restriction Fragment Southern Blot
Telomere length was measured by HinfI/RsaI digestion of genomic DNA, separation by agarose gel electrophoresis, transfer to nylon membrane, and probing with a 32 P-labeled telomeric probe, using standard techniques (de Lange, 1992) . The hTERT antibody CMRI 276-294 and antigenic release peptide are available to researchers from Abbexa, under exclusive license from the authors' institution, Children's Medical Research Institute. 
